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Summary
Background Several high-income countries have pre-entry screening programmes for tuberculosis. We aimed to 
establish the yield of pre-entry screening programmes to inform evidence-based policy for migrant health screening.
Methods We searched six bibliographic databases for experimental or observational studies and systematic reviews, 
which reported data on migrant screening for active or latent tuberculosis by any method before migration to a 
low-incidence country. Primary outcomes were principal reported screening yield of active tuberculosis, yield of 
culture-conﬁ rmed cases, and yield of sputum smear for acid-fast bacilli cases. Where appropriate, ﬁ xed-eﬀ ects models 
were used to summarise the yield of pre-entry screening across included studies.
Findings We identiﬁ ed 15 unique studies with data for 3 739 266 migrants screened pre-entry for tuberculosis between 
1982 and 2010. Heterogeneity was high for all primary outcomes. After stratiﬁ cation by prevalence in country of 
origin, heterogeneity was reduced for culture-conﬁ rmed and smear-conﬁ rmed cases. Yield of culture-conﬁ rmed cases 
increased with prevalence in the country of origin, and summary estimates ranged from 19·7 (95% CI 10·3–31·5) 
cases identiﬁ ed per 100 000 individuals screened in countries with a prevalence of 50–149 cases per 100 000 population 
to 335·9 (283·0–393·2) per 100 000 in countries with a prevalence of greater than 350 per 100 000 population.
Interpretation Targeting high-prevalence countries could result in the highest yield for active disease. Pre-entry screening 
should be considered as part of a broad package of measures to ensure early diagnosis and eﬀ ective management of 
migrants with active tuberculosis, and be integrated with initiatives that address the health needs of migrants.
Funding Wellcome Trust, UK National Institute for Health Research, Medical Research Council, Public Health 
England.
Copyright © Aldridge et al. Open Access article distributed under the terms of CC BY.
Introduction
Several high-income countries (Australia, Austria, 
Canada, France, Israel, Jordan, New Zealand, and USA) 
have pre-entry screening programmes for tuberculosis.1 
The UK has used a combination of upon-entry and 
post-entry screening for several decades, but fully 
transitioned to pre-entry screening on April 1, 2014.2 
Migration patterns have led to recent changes in the 
epidemiological proﬁ le of cases in low-incidence settings. 
In Europe there has been an absolute decrease in the 
number of tuberculosis cases reported, but only 
ﬁ ve countries report a decrease in migrant populations, 
ten report no change, and 11 report an increase.3,4 The 
overall proportion of tuberculosis cases in individuals of 
foreign origin in Europe is 25·8%; however, many 
countries have much higher proportions, such as Sweden 
(89·4%), Norway (87·8%), and the UK (70·1%).5,6 In the 
USA, the overall number of tuberculosis cases has been 
decreasing, but notiﬁ cations in foreign-born individuals 
are 11·5 times higher than those born in the country.7
The number of people residing outside their country 
of birth is substantial. The UN Population Division 
estimated that globally this population consisted of 
232 million people in 2013.8,9 Between 1990 and 2013, 
North America accepted the largest gross inﬂ ow of 
migrants at 25 million, and Europe had the second 
largest at 23 million. A substantial number of migrants 
move from countries with a high incidence of 
tuberculosis to those with a low incidence. Reasons for 
migration include economics (to work in the receiving 
country or move away from ﬁ nancial crises in the 
country of origin), education, political instability or war, 
natural disasters, and reunion (joining family members 
in the receiving country).10,11
Because of the high burden of tuberculosis in migrants, 
many governments in low-incidence settings have imple-
mented screening programmes. Tuberculosis screening 
programmes for migrants can occur at three points in 
time: pre-entry (before entering the country), upon entry, 
or post-entry. Many European countries have implemented 
post-entry screening and, although there are diﬀ erences 
in the screening approach, the characteristics of such 
programmes are well documented.12
The yield of pre-entry screening programmes for 
tuberculosis can diﬀ er from upon-entry and post-entry 
programmes. With some exceptions, upon-entry and 
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post-entry screening tend not to be a compulsory part of 
visa applications; therefore, individuals undergoing 
screening might not be representative of the wider migrant 
population. Attendance for screening could be determined 
by patient health-seeking behaviour or the opinion 
of immigration staﬀ . Conversely, pre-entry screening 
programmes are typically a compulsory part of the visa 
application process and as a result coverage is higher, if not 
complete, and such studies should be fully representative 
of the populations screened and intending to migrate.
The characteristics of post-entry and upon-entry 
screening programmes have been well documented, but 
we are not aware of any previous studies that have 
systematically reviewed the yield of pre-entry screening 
programmes.12–14 Therefore, our aim was to establish the 
yield of pre-entry screening programmes for active disease 
and latent infection to inform future evidence-based 
policy for migrant health-screening initiatives.
Methods
Search strategy and selection criteria
We searched for reports published after Jan 1, 1980, in 
Medline, Embase, LILACS, Cochrane Infectious Diseases 
Group Specialized Register, Cochrane Library, Conference 
Proceedings Citation Index–Science, and Conference 
Proceedings Citation Index–Social Science & Humanities. 
Reference lists of included studies were hand-searched 
to identify further relevant work.
Detailed search terms for the bibliographic databases 
are presented in the appendix. In summary, terms 
covered the populations of interest (migrants, refugees, 
asylum seekers, new entrants, undocumented migrants), 
the intervention (pre-entry screening), and standard 
terms for tuberculosis.
Initial search results were imported into EPPI-
Reviewer 4 where duplicates were identiﬁ ed and 
removed. An updated search was done on April 1, 2014, 
with Zotero.15,16 RWA, TAY, and DZ screened titles, 
abstracts, and full-text reports. Disagreements were 
resolved by discussion, and remaining issues were 
assessed in conjunction with a fourth reviewer (ACH). 
Data from included studies were extracted in duplicate 
to an Excel spreadsheet (Microsoft Oﬃ  ce for Mac 2011).
We prespeciﬁ ed several study types as eligible for 
inclusion: experimental studies (randomised controlled 
trials and quasi-randomised controlled trials, including 
before and after studies), observational studies (including 
retrospective and prospective cohort studies, case-control 
studies, cross-sectional and case series), and systematic 
reviews. Additional inclusion criteria were that a study 
needed to be published with an abstract in English, it 
needed to report the total number of individuals screened 
who plan to migrate and the number of cases of 
tuberculosis infection or disease identiﬁ ed, and screening 
needed to have taken place before the migrant entered a 
low-incidence country. Eligible studies could screen for 
tuberculosis by any method including radiographic, 
microbiological, and a clinician’s recommendation to treat 
an individual on the basis of clinical or radiological signs 
or symptoms compatible with tuberculosis. We followed 
the PRISMA reporting guidelines.
Deﬁ nitions
We used the deﬁ nition of migrants developed by Hans 
Rieder and colleagues17 and used in a recent systematic 
review of screening in the European Union.12 It classiﬁ es 
migrants into the four groups: migrant (a foreigner 
legally admitted and expected to settle in a host country), 
asylum seeker (a person wishing to be admitted to a 
country as a refugee and awaiting decision on their 
application for refugee status under relevant 
international instruments), foreign-born citizen (a 
person who is a national of the state in which they are 
present but who was born in another country), and 
undocumented foreigner or migrant (formerly classiﬁ ed 
as illegal, describing an individual who enters, stays, or 
works in a host country without an appropriate residence 
permit or visa).
There is no universally accepted deﬁ nition of a 
low-incidence tuberculosis country. For the purpose of 
our analysis, we used the European Centre for Disease 
Prevention and Control deﬁ nition of a low-incidence 
country as one with a notiﬁ cation rate below 20 cases per 
100 000 in the general population.18
Outcomes
We considered three primary outcomes: the principal 
yield of pre-entry screening for active tuberculosis 
reported for each study (detected by any method), yield 
of active tuberculosis cases conﬁ rmed by culture, and 
yield of active tuberculosis cases conﬁ rmed by smear for 
See Online for appendix
Figure 1: Study proﬁ le
1902 records screened
1745 records excluded as not relevant or duplicates
157 full-text articles assessed for eligibility
138 full-text articles excluded
19 studies meeting inclusion criteria
4 studies excluded because of overlapping data 
    with other studies
15 studies included in quantitative synthesis
1887 records identified through database searching 
            from Jan 1, 1980 to April 1, 2014
15 additional records identified through other 
      sources on April 1, 2014
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acid-fast bacilli. Secondary outcomes were yield of active 
cases detected by radiography, yield of drug-resistant 
active disease, yield of latent tuberculosis (diagnosed by 
any method), costs associated with screening individual 
migrants, and costs of treatment for individuals screened 
and found to have tuberculosis.19
Year of 
publication
Screening method Principal case 
deﬁ nition
Number 
screened
Cases 
identiﬁ ed
Yield per 
100 000 
population 
screened
Population 
screened
Country 
of origin
Receiving 
country
Country 
where 
screening 
took place
Years 
screened
Bollini et al25 1998 Chest radiograph; if 
compatible with tuberculosis, 
sputum smear samples were 
taken on 3 consecutive days
One or more 
positive samples by 
sputum smear
131 241 729 555 Migrants Vietnam USA, 
Australia, 
Canada
Vietnam 1992–94
Dasgupta 
et al27
2000 Chest radiograph; if 
compatible with tuberculosis, 
sputum smear samples and 
tuberculin tests when judged 
as appropriate
Culture positive or 
radiographic 
improvement after 
at least 2 months 
therapy
12 898 17 132 Migrants Multiple Canada Multiple 1996–97
Gorbacheva 
et al26
2010 Chest radiograph, clinical 
examination, history, and 
tuberculin skin test; 
three sputum specimens in 
those with ﬁ ndings that 
suggested tuberculosis
One or more 
positive sample by 
sputum smear or 
culture
23 459 151 644 Refugees Bhutan USA, Canada, 
Australia, 
New Zealand, 
Denmark, 
Norway
Nepal 2007–09
King et al28 2011 Chest radiograph; if 
compatible with tuberculosis, 
sputum smear and culture 
testing*
Clinical cases, or one 
or more positive 
samples by sputum 
smear or culture
378 939 519 137 Migrants Multiple Australia Multiple 2009–10
Lange et al29 1989 5 tuberculin units of puriﬁ ed 
protein derivative
10 mm induration 
after puriﬁ ed 
protein derivative 
test
873 9 1031 Adoptees South 
Korea
USA South Korea 1985–88
Lui et al30 2009 Chest radiograph; if 
compatible with tuberculosis, 
sputum smear samples were 
taken on 3 consecutive days
Inactive 
tuberculosis: 
radiograph-
positive, acid-fast 
bacilli sputum 
smear-negative 
tuberculosis
3 092 729 29 998 970 Mixed Multiple USA Multiple 1999–2005
Malone 
et al31
1994 Chest radiograph and physical 
examination; if compatible 
with tuberculosis, sputum 
smear and culture testing on 
three consecutive samples
Presumptive active 
tuberculosis†
11 000 340 3091 Migrants Haiti USA US naval 
base in 
Guantanamo 
Bay, Cuba
1991–93
Maloney 
et al32
2006 Chest radiograph; if 
compatible with tuberculosis, 
sputum smear and culture 
testing on three consecutive 
samples
Acid-fast bacilli 
sputum 
smear-positive or 
culture-positive 
cases
14 098 183 582 Migrants Vietnam USA Vietnam 1998–99
Mor et al33 2012 Chest radiograph, clinical 
examination, history, and 
tuberculin skin test; 
three sputum specimens in 
those with ﬁ ndings that 
suggested tuberculosis
Active pulmonary 
tuberculosis‡
13 379 57 426 Migrants Ethiopia Israel Ethiopia 2001–05
Oeltmann 
et al34
2008 Chest radiograph, clinical 
examination, and history; 
three sputum specimens in 
those with ﬁ ndings that 
suggested tuberculosis
Clinical and 
acid-fast bacilli 
sputum 
smear-positive 
cases
15 455 272 1760 Refugees Laos USA Thailand 2004–05
Painter 
et al35
2013 Chest radiograph, clinical 
examination, history, and 
sputum testing for 
Mycobacterium tuberculosis as 
per CDC 2009 technical 
instructions
QuantiFERON—TB 
Gold In-Tube Assay 
and tuberculin skin 
test positive§
1475 859 Not 
applicable¶
Migrants Vietnam USA Vietnam 2008–10
(Table 1 continues on next page)
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Year of 
publication
Screening method Principal case 
deﬁ nition
Number 
screened
Cases 
identiﬁ ed
Yield per 
100 000 
population 
screened
Population 
screened
Country 
of origin
Receiving 
country
Country 
where 
screening 
took place
Years 
screened
(Continued from previous page)
Plant et al36 2004 Chest radiograph, clinical 
examination, and history; 
three sputum specimens in 
those with ﬁ ndings that 
suggested tuberculosis
Acid-fast bacilli 
sputum 
smear-positive or 
culture-positive 
cases
6018 36 598 Migrants Vietnam Australia Vietnam 1997–2001
Wang et al37 1991 Chest radiograph followed by 
three sputum cultures in 
those with ﬁ ndings that 
suggested tuberculosis
Inactive 
tuberculosis||
21 956 1173 5343 Migrants Multiple Canada Multiple 1982–85
Watkins 
et al38
2005 Chest radiograph Radiograph-
positive cases
1669 170 10 186 Migrants Vietnam Australia Vietnam Not stated
Yanni et al39 2013 Chest radiograph, clinical 
examination, history, and 
sputum testing for 
M tuberculosis as per CDC 
2009 technical instructions
One or more 
positive samples by 
sputum smear or 
culture
14 077 1 7 Refugees Iraq USA Jordan 2007–09
*Limitations in sputum smear and culture methods were reported by study authors. †Full deﬁ nition not provided and unable to contact corresponding author. ‡Symptomatic patient with pulmonary disease and 
conﬁ rmed Mycobacterium tuberculosis complex culture. §Following the results of chest radiograph, applicants were invited to participate in a study of the tuberculin skin test and QuantiFERON—TB Gold In-Tube 
Assay for which they would be provided the results, but the result of which would not aﬀ ect their visa application; varying size of the tuberculin skin test induration was used as cutoﬀ . ¶Yield for latent 
tuberculosis for this study is not presented since the primary aim of the study was to compare the sensitivity of QuantiFERON—TB Gold In-Tube Assay with the tuberculin skin test for culture-positive pulmonary 
tuberculosis; therefore, it was done on a sample of migrants with and without abnormal radiograph results, and therefore yield of latent tuberculosis will not be representative. ||Inactive tuberculosis deﬁ ned by 
authors as “radiograph shows evidence of tuberculosis, it is repeated at a minimum interval of 3 months to conﬁ rm stability of the lesion. In addition, three sputum cultures, incubated for 7–8 weeks, taken at 
least 24 h apart, are required to be negative”.
Table 1: Studies reviewed
Figure 2: Forest plot of pre-entry screening programme yield for principal outcome of active tuberculosis cases found by each study (case deﬁ nition varies 
between studies, sorted by year of publication)
0 1000 2000 3000 4000
Yield per 100 000 population screened
Malone et al,31 1991−93; presumptive active tuberculosis
Bollini et al,25 1992−94; one or more positive sample by sputum smear
Dasgupta et al,27 1996−97; the presence of cultures positive for 
Mycobacterium tuberculosis or radiographic improvement after at least 
2 months of therapy for active disease
Plant et al,36 1997−2001; acid-fast bacilli sputum smear-positive or culture-positive
cases, or both
Maloney et al,32 1998−99; acid-fast bacilli sputum smear, or culture positive cases
Oeltmann et al,34 2004−05; clinical and acid-fast bacilli sputum smear-positive cases
Gorbacheva et al,26 2007−09; one or more positive sample by sputum 
smear, or culture, or both
King et al,28 2009−10; clinical cases, or one or more positive sample by sputum 
smear or culture, or both
Mor et al,33 2001−05; active pulmonary tuberculosis
Yanni et al,39 2007−09; one or more positive sample by sputum smear, or culture, or both
 3090·9 (2775·5–3422·7)
 
 555·5 (516·0–596·4)
 131·8 (75·7–202·7)
 598·2 (417·8–810·1)
 
581·6 (462·5–714·3)
 1759·9 (1558·5–1973·4)
 643·7 (545·2–750·2)
 137·0 (125·4–149·0)
 426·0 (322·3–544·0)
 7·1 (0·0–30·5)
Study, years screened; case deﬁnition Yield (95% CI)
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Statistical analysis
We used ﬁ xed-eﬀ ects models with Freeman-Tukey 
transformation of data to estimate summary yield of 
pre-entry screening across studies and subgroups where 
appropriate.20,21 We used the I² transformation to 
describe the proportion of total variation in study 
estimates that is due to heterogeneity.22 Where we 
identiﬁ ed overlapping data on an individual screening 
programme, we included the publication with the 
largest amount of data (by time period or number of 
individuals screened). Where appropriate, we presented 
economic components of the studies in a narrative 
format.
We did a subgroup analysis for the primary outcomes 
to assess the eﬀ ect of prevalence in the country of origin, 
the screening method used (eg, radiographic, 
microbiological, clinical), the receiving country, and the 
type of migrants screened. Because there are no 
universally accepted categories to classify prevalence of 
tuberculosis at the country level, we chose to use the 
following groups: 20–49, 50–149, 150–249, 250–349, and 
350 or more cases per 100 000 population. We used WHO 
prevalence estimates for the middle year in which 
screening was done.23 Where possible, we extracted data 
for primary outcomes for each of the subgroups (eg, 
diﬀ erent countries of origin) and then included them in 
the subgroup analysis.
RWA and TAY independently assessed the risk of 
bias for included studies with the Grading of 
Recommendations Assesssment, Development, and 
Evaluation (GRADE)  approach.24 Any disagreements were 
discussed and resolved with the help of a third reviewer 
(ACH) where necessary.
Role of the funding source
The study sponsors had no role in study design, the 
collection, analysis, and interpretation of data. The 
corresponding author conﬁ rms that he had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Number 
screened
Total cases of 
active disease 
identiﬁ ed
Smear-
positive 
cases
Culture-
positive 
cases
Multidrug-
resistant 
cases
Radiograph-
positive cases
Latent 
tuberculosis 
cases
Population 
screened
Country of 
origin
Receiving country
Bollini et al25 131 241 729 (0·6%) 729 (0·6%) ·· ·· ·· ·· Migrants Vietnam US, Australia, Canada
Dasgupta et al27 12 898 17 (0·1%) ·· ·· ·· 722 (5·6%) 353 (2·7%) Migrants Multiple Canada
Gorbacheva et al26 23 459 151 (0·6%) 54 (0·2%) ·· ·· ·· ·· Refugees Bhutan USA, Canada, Australia, 
New Zealand, Denmark, 
Norway
King et al28* 12 795 113 (0·9%) 4 (0·0%) 43 (0·3%) ·· ·· ·· Migrants Philippines Australia
King et al28* 59 666 87 (0·1%) 2 (0·0%) 24 (0·0%) ·· ·· ·· Migrants India Australia
King et al28* 13 621 84 (0·6%) 6 (0·0%) 43 (0·3%) ·· ·· ·· Migrants Vietnam Australia
King et al28* 71 600 43 (0·1%) 1 (0·0%) 14 (0·0%) ·· ·· ·· Migrants China Australia
King et al28* 42 503 24 (0·1%) 2 (0·0%) 8 (0·0%) ·· ·· ·· Migrants South Korea Australia
King et al28* 12 859 20 (0·2%) 0 8 (0·1%) ·· ·· ·· Migrants Malaysia Australia
King et al28* 9192 15 (0·2%) 1 (0·0%) 0 ·· ·· ·· Migrants Indonesia Australia
King et al28* 1512 14 (0·9%) 1 (0·1%) 10 (0·7%) ·· ·· ·· Migrants Cambodia Australia
King et al28* 10 608 13 (0·1%) 0 2 (0·0%) ·· ·· ·· Migrants Thailand Australia
King et al28* 2861 12 (0·4%) 0 5 (0·2%) ·· ·· ·· Migrants Nepal Australia
Lange et al29 873 9 (1·0%) ·· ·· ·· ·· 9 (1·0%) Adoptees South Korea USA
Lui et al30 2 714 223 26 075 (1·0%) ·· ·· ·· 26 075 (1·0%) ·· Migrants Multiple USA
Lui et al30 378 506 3923 (1·0%) ·· ·· ·· 3923 (1·0%) ·· Refugees Multiple USA
Malone et al31 11 000 340 (3·1%) ·· 37 (0·3%) ·· ·· Migrants Haiti USA
Maloney et al32 14 098 82 (0·6%) 82 (0·6%) 183 (1·3%) 5 (0·0) 1331 (9·4%) ·· Migrants Vietnam USA
Mor et al33 13 379 57 (0·4%) ·· 37 (0·3%) ·· 150 (1·1%) ·· Migrants Ethiopia Israel
Oeltmann et al34 15 455 272 (1·8%) 34 (0·2%) 57 (0·4%) 24 (0·2%) ·· ·· Refugees Laos USA
Oeltmann et al34 5637 1624 (28·8%) ·· ·· ·· ·· 1624 (28·8%) Refugees Laos USA
Painter et al35 20 100 211 (1·0%) 211 (1·0%) ·· 2087 (10·4%) ·· Migrants Vietnam USA
Plant et al36 5108 25 (0·5%) 15 (0·3%) ·· ·· ·· ·· Migrants Vietnam Australia
Plant et al36 910 11 (1·2%) 6 (0·7%) ·· ·· ·· ·· Migrants Cambodia Australia
Wang et al 37 21 956 1173 (5·3%) ·· ·· ·· ·· ·· Migrants Multiple Canada
Watkins et al38 1669 170 (10·2%) ·· ·· ·· 170 (10·2%) ·· Migrants Vietnam Australia
Yanni et al39 14 077 1 (0·0%) ··  ·· ··  ·· 251 (1·8%) Refugees Iraq USA
*Study reports that overall 230 cases were culture conﬁ rmed and 67 were smear positive, but not all of these data are included as the data on number of migrants screened was not presented for all countries.
 Table 2: Studies included within the quantitative review
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Results
A search of six bibliographic databases was done on April 
5, 2013, and updated on April 1, 2014. 1887 studies were 
identiﬁ ed (ﬁ gure 1). 15 more reports were identiﬁ ed 
through other sources, including the review of references 
of included studies. 157 full-text articles were retrieved 
and assessed for eligibility, and 19 manuscripts met the 
inclusion criteria after double screening and review.25–43 
After further review and extraction of data, four studies 
were excluded from the ﬁ nal analysis because they 
contained overlapping data for the primary outcomes.40–43
The 15 studies included in the ﬁ nal analysis reported 
data on 3 739 266 individual migrants screened between 
1982 and 2010 (table 1).25–39 The smallest study had data on 
873 migrants and the largest 3 092 729 migrants. Screening 
protocols varied between studies, but many included an 
initial chest radiograph, clinical examination, and testing 
for smear and culture. The principal outcome for 
ten studies reporting data on active tuberculosis included 
a combination of smear, culture, or intention to treat on 
the basis of clinical ﬁ ndings as part of their case deﬁ nition 
(ﬁ gure 2). Meta-analyses of yield for all three primary 
outcomes showed high levels of heterogeneity (I²>90%) 
and therefore we did not calculate summary eﬀ ect 
estimates across studies.
No studies reported the number of individuals tested by 
sputum culture or smear and therefore it was only possible 
to calculate yield based on the total number of individuals 
screened, and not by total number of microbiological tests 
done (table 2). Six studies presented data on 755 cases that 
were culture conﬁ rmed among 452 971 individuals initially 
screened.27,28,31–35 Six studies had data on smear-positive 
cases of tuberculosis, with 987 cases identiﬁ ed in the 
569 210 individuals initially screened.25,26,28,32,34,36 Most studies 
reported sputum smear testing on three samples for those 
individuals with radiograph or clinical symptoms that 
suggested tuberculosis (appendix). Some variation existed 
in the number of positive samples needed to classify 
individuals with smear-positive disease.
After stratifying results by prevalence of tuberculosis in 
the country of origin, heterogeneity was reduced for 
culture-positive and smear-positive conﬁ rmed cases, but 
not the principal outcome—active tuberculosis cases 
(ﬁ gure 3, appendix). There was an increasing yield of 
culture-positive and smear-positive cases with increasing 
prevalence in the country of origin. Summary estimates 
of yield of culture-positive cases ranged from 19·7 
(95% CI 10·3–31·5) cases identiﬁ ed per 100 000 
individuals screened in countries with a prevalence 
of 50–149 cases per 100 000 population to 335·9 
(283·0–393·2) per 100 000 in countries with a prevalence 
of greater than 350 per 100 000 population (ﬁ gure 3). The 
results of the meta-analyses were dominated by one large 
study, which acknowledged some limitations with data 
for smear and culture testing because this was not 
uniformly done across all sites and for all cases.28 Across 
all included studies, prevalence of culture-conﬁ rmed 
cases was highest in migrants to the USA from Vietnam 
with 1298 cases per 100 000 individuals screened (95% CI 
1118–1499; appendix).
Figure 3: Forest plot of pre-entry screening programme yield of culture-positive cases of tuberculosis, stratiﬁ ed by WHO prevalence of tuberculosis in country 
of origin (sorted by prevalence in country of origin)
0 250 500 750 1000 1250 1500
Yield per 100 000
 62·2 (25·3 –114·0)
 19·6 (10·5–31·3)
 19·7 (10·3–31·5)
 18·8 (7·7–34·5)
 18·9 (0·3–56·8)
 315·7 (228·0–417·4)
 1049·8 (913·4–1195·5)
 174·8 (48·7–368·3)
 166·2 (140·1–194·4)
 40·2 (25·6–58·1)
 0·0 (0·0–18·7)
 1298·1 (1117·6–1491·8)
 336·4 (236·1–454·0)
 133·5 (110·7–158·4)
 276·6 (194·1–373·3)
 336·1 (242·7–444·4)
 368·8 (279·0–471·0)
 661·4 (306·1–1142·2)
 335·9 (283·0–393·2)
50−149 cases per 100 000 population
King et al,28 2009−10, Malaysia
King et al,28 2009−10, China
Summary estimate (I2=82·6%, p=0·0166)
150−249 cases per 100 000 population
King et al,28 2009−10, South Korea
King et al,28 2009−10, Thailand
King et al,28 2009−10, Vietnam
Painter et al,35 2008−10, Vietnam
King et al,28 2009−10, Nepal
Summary estimate (I2=99·1%, p<0·0001)
250−349 cases per 100 000 population
King et al,28 2009−10, India
King et al,28 2009−10, Indonesia
Maloney et al,32 1998−99, Vietnam
Malone et al,31 1991−93, Haiti
Summary estimate (I2=99·3%, p=<0·0001)
≥350 cases per 100 000 population
Mor et al,33 2001−05, Ethiopia
King et al,28 2009−10, Philippines
Oeltmann et al,34 2004−05, Laos
King et al,28 2009−10, Cambodia
Summary estimate (I2=48·1%, p=0·1227)
Study, years screened, country of origin Yield (95% CI)
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With the exception of culture-conﬁ rmed cases in 
refugees (I²=0%, p=0·85), heterogeneity remained high 
for all three primary outcomes (I²>90%) after stratifying 
by population, screening method, and receiving country 
(full results are presented in the appendix).
In the studies that reported data on culture-conﬁ rmed 
cases, three described yield of multidrug-resistant 
tuberculosis. 33 cases in 183 individuals with culture-
conﬁ rmed disease were found in these three studies.28,32,34 
Although most studies had radiographic screening as a 
ﬁ rst-line test, numerator and denominator data for this 
speciﬁ c outcome were only presented in ﬁ ve studies.27,30,32,33,38 
34 495 chest radiograph-positive cases were reported 
among the 3 154 873 individuals screened, and probably 
included both active and inactive (or old) tuberculosis. Not 
all studies provided details as to how radiographs were 
analysed and classiﬁ ed, which might result in a great deal 
of variation between studies.
Three studies reported data on latent tuberculosis 
infection, with 1884 latent infections identiﬁ ed in 
20 587 individuals screened (varying tests and cutoﬀ s 
were used—see appendix).29,34,39 One study reported 
tests for latent tuberculosis on a sample of migrants on 
the basis of radiograph results (testing 1000 applicants 
with radiographic ﬁ ndings consistent with active 
tuberculosis and 500 applicants with a normal 
radiograph). Therefore, the yield of latent tuberculosis 
from this study does not represent population 
prevalence of latent tuberculosis infection and the 
results were not included in this secondary analysis.35
Cost-eﬀ ectiveness was examined in one study with data 
from the Canadian pre-entry migrant screening 
pro gramme from June, 1996, to June, 1997. Compared with 
passive detection of cases after arrival in Canada, this study 
estimated the incremental cost (savings) to treat each case 
of prevalent active tuberculosis detected pre-entry as 
CAN$39 409.27 A further study, using data presented in this 
systematic review,33 estimated the cost of running a health 
station for an active tuberculosis screening programme in 
Ethiopia at US$60 100 for about 3500 individuals screened 
per annum.44 No data were found on costs of treatment for 
individuals screened and identiﬁ ed as having tuberculosis.
We used GRADE criteria to assess the risk of bias of 
included studies (table 3). All included studies were 
observational in nature and therefore the evidence for 
each outcome was initially determined as low (as per 
the GRADE methodology). This systematic review 
focuses on describing yield of existing screening 
programmes in operational settings and therefore 
observational studies are an appropriate study design. 
Most studies were at risk of bias because of the 
eligibility criteria applied, and the reporting and 
measure ment of exposure and outcome data. Sub-
stantial heterogeneity existed for primary outcomes, 
with CIs across studies showing minimal or no overlap 
with the exception of culture-conﬁ rmed and smear-
conﬁ rmed disease when stratiﬁ ed by prevalence in 
country of origin. Because of these limitations, the 
quality of evidence for all outcomes was downgraded to 
very low.
Discussion
We identiﬁ ed data on nearly 4 million migrants screened 
pre-entry and found that yield for culture-conﬁ rmed and 
Study design Quality assessment Quality Importance
Number 
of studies
Risk of bias Inconsistency Indirectness Imprecision Other considerations
Principal outcome Observational* 15 Serious† ‡ Very serious§ Serious¶ || No serious imprecision Reporting bias**
dose response gradient††
Very low Important
Sputum culture Observational* 6 Serious† ‡‡ Serious§§ Serious¶ ¶¶ No serious imprecision Reporting bias**
dose response gradient††
Very low Important
Sputum smear Observational* 6 Serious† ‡‡ Serious§§ Serious¶ ¶¶ No serious imprecision Reporting bias** Very low Important
Chest radiograph Observational* 5 Serious† Very serious§ Very serious¶ || No serious imprecision Reporting bias** Very low Important
Latent tuberculosis Observational* 3 Serious† Very serious§ Very serious¶ No serious imprecision Reporting bias** Very low Not important
Multidrug-resistant 
tuberculosis
Observational* 3 Serious† ‡‡ Serious§§ Serious¶ ¶¶ No serious imprecision Reporting bias** Very low Important
*Case series. †Most studies were at some risk of bias for failure to develop and apply appropriate eligibility criteria and measurements of outcome that had limitations. ‡Largest study for analysis by subgroup28 
stated that “smear and culture testing may be oﬀ ered but of variable quality”. Several studies only look back at results of individuals who arrived in the low-incidence country—a potential bias if there was a 
diﬀ erence in the proportion who travelled by test result, which is likely to be the case. §Substantial heterogeneity existed among studies with CIs that minimally overlapped. The proportion of the variation in point 
estimates due to among-study diﬀ erences was large and exploration of a-priori subgroup analyses did not substantially explain this. ¶Populations across studies varied; however, the evidence summaries are highly 
relevant to policy makers and those interpreting the studies, and outcomes (such as active tuberculosis) are likely to be of interest and important to migrants. ||Interventions and outcomes varied greatly, 
particularly as smear and culture testing was oﬀ ered but of variable quality in the largest included study for analysis by subgroup28 and as many studies included radiographic diagnoses with substantial variation in 
the radiographic case deﬁ nition used. Additionally, studies with high detection rates (Watkins et al38) seem likely to have included inactive and old tuberculosis scars in addition to active disease. **Data for all years 
from countries conducting pre-entry screening were not available in the published literature. ††Some evidence to suggest that higher tuberculosis prevalence in country conducting pre-entry screening was 
associated with a higher yield of cases. ‡‡There was the potential for outbreak bias in one study34 because it was initiated as a result of an unusually high number of cases. §§Substantial heterogeneity among 
studies with CIs that showed minimal or no overlap. The proportion of the variation in point estimates due to between-study diﬀ erences was large. Exploration of a-priori subgroups reduced heterogeneity. 
¶¶Interventions and outcomes for multidrug-resistant cases are likely to be less variable due to procedures involved in laboratory testing being somewhat uniform across sites, although the consistency with 
which these were applied across studies might cause some issues in relation to indirectness.
 Table 3: GRADE summary of ﬁ ndings and quality of evidence for the primary and secondary outcomes
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smear-conﬁ rmed cases was highest when screening was 
done in high-prevalence countries. Only two studies 
presented data on the associated costs or cost eﬀ ectiveness 
of their pre-entry screening programme. To our 
knowledge, this is the ﬁ rst systematic review and meta-
analysis of pre-entry screening programme data for 
tuberculosis, which identiﬁ ed 15 studies with unique 
data on this topic. We used established systematic review 
procedures including double screening review, and 
PRISMA reporting guidelines for systematic reviews and 
meta-analyses.19 We attempted to reduce bias in the 
review process by following empirically based review 
guidelines.24
There was substantial heterogeneity between studies, 
limiting our ability to synthesise results across settings 
and outcomes. With the exception of yield of 
culture-conﬁ rmed and smear-conﬁ rmed cases, when 
stratiﬁ ed by prevalence of tuberculosis in country of 
origin, and culture-conﬁ rmed cases in refugees, 
heterogeneity in the primary and secondary outcomes 
remained high after exploring potential a-priori 
explanatory variables. Data on the age of those screened 
was not provided consistently, which might be 
particularly important for latent tuberculosis and studies 
that included old tuberculosis detected by chest 
radiograph. The top ﬁ ve countries of origin for migrants 
from developing to developed countries in 2010 were 
Mexico, India, China, Philippines, and Turkey.11 Although 
data are presented for India, China, and the Philippines, 
the migrants are not entirely representative of migrant 
ﬂ ow between developing and developed countries. It was 
not clear from most studies whether there was uniform 
drug susceptibility testing or whether only retreatment 
cases were tested. There was a risk of misclassiﬁ cation in 
the principal outcomes reported by many studies, 
particularly for those that included clinically identiﬁ ed 
cases (with an intention to treat) as part of the case 
deﬁ nition.
A previously published systematic review focused on all 
types of migrant screening programmes for tuberculosis 
in the European Union and European Economic Area, 
independent of where the screening took place.12 The 
review by Klinkenberg and colleagues12 did not identify 
any studies of pre-entry screening by European countries; 
however, data were separately reported from three pre-
entry screening programmes performed by countries 
outside the European Union and European Economic 
Area. All studies of non-European Union studies were 
identiﬁ ed and included in our systematic review. A total of 
14 studies reported data from upon-entry screening 
programmes in the European Union and European 
Economic Area with a median active tuberculosis yield of 
360 (IQR 100–520) cases per 100 000 people screened. Five 
studies reported data on community post-entry screening 
with a summary median active tuberculosis yield of 220 
(IQR 100–380) cases per 100 000 people invited to 
screening. Direct comparisons with upon-entry and 
post-entry screening programmes are diﬃ  cult to make 
because of the lack of comparability between study 
designs, secular trends, and the populations considered. 
Pre-entry screening, when done in countries with a 
prevalence of tuberculosis greater than 350 per 100 000 
population seems to be within a similar range as these 
upon-entry and post-entry programmes.
Pre-entry screening programmes aim to identify cases 
of active tuberculosis before arrival of the migrant in the 
host country. Our review provides evidence that pre-entry 
screening programmes have varying yield that increases 
with prevalence in the country of origin. Screening in 
countries with prevalence of less than 150 per 100 000 will 
probably result in low yield of culture-conﬁ rmed and 
smear-conﬁ rmed cases.
Pre-entry screening programmes might need the 
migrant to cover the bulk of costs of testing and 
treatment; however, the programmes still might not be 
entirely cost-neutral for the receiving country because of 
the governance and oversight needed for appropriate 
operation. The paucity of cost-eﬀ ectiveness data on these 
schemes should therefore be addressed because there is 
uncertainty of the value of pre-entry screening compared 
with other tuberculosis control activities.
Data from surveillance programmes around the world 
suggest that rates of disease in migrants from 
high-incidence countries remain high for many years 
after entry, so tuberculosis control programmes in 
low-incidence countries should not rely entirely on 
pre-entry screening for active tuberculosis in 
migrants.7,45–47 For example, in the UK, 50% of tuber-
culosis in migrant groups occurs more than 5 years after 
entry.6 Additionally, these schemes could miss 
tuberculosis following unplanned migration and in 
undocumented migrants who might have higher risk. 
Health care provision for migrants after arrival to a host 
country and other tuberculosis control measures should 
therefore remain a priority, because screening migrants 
will not prevent a high proportion of future cases of 
disease.
Emerging evidence suggests that domestic returns for 
investment in tuberculosis control programmes overseas 
might make them cost eﬀ ective, and policy makers 
might wish to consider implementation alongside 
pre-entry screening programmes.48,49 Such an enlightened 
self-interest approach to global tuberculosis control 
might be not only more cost eﬀ ective, but also could 
overcome screening-induced inequalities, so that a 
greater number of individuals in need beneﬁ t from 
treatment, not just those in a position to leave their 
country of origin. This broader view would enhance 
global collaboration in eﬀ orts to eliminate tuberculosis.
In many low-incidence countries, risk of tuberculosis is 
greatest in migrant populations. Some of this disease can 
be identiﬁ ed by pre-entry screening with the highest yield 
achieved when programmes focus on high-prevalence 
countries. Pre-entry screening might therefore make a 
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contribution to control within the receiving country, but 
the cost-eﬀ ectiveness remains unclear and where the cost 
of screening is borne by the migrant or their country of 
origin this might increase inequalities. When used, 
pre-entry screening should therefore be considered as 
part of a broader package of measures to ensure early 
diagnosis and eﬀ ective management of migrants with 
active tuberculosis, and be integrated with other initiatives 
addressing the health needs of migrants.
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